In the first quarter of 2026, SonoScape Medical leveraged multiple drivers, including the recovery of domestic medical terminal procurement, a continued increase in high-end product market share, and steady expansion in overseas markets, to elevate its operational performance to a new level. This fully demonstrates that the company’s multi-product line layout, high-end strategy, and R&D innovation achievements have entered a period of concentrated realization, and effectively confirms the company’s development resilience as an industry leader. Looking ahead to the full year of 2026, with hospital terminal procurement stabilizing and market demand continuing to improve, the company’s performance scale and profitability quality are expected to achieve dual growth.
During the reporting period, the company’s four core product lines maintained high momentum, further solidifying the pattern of multi-business synergistic growth. As the company’s foundational business, the ultrasound segment sustained steady growth, firmly ranking among the top two domestically and top ten globally, with its core competitiveness continuing to lead. In 2026, the company will launch a new version of the 80-series high-end ultrasound platform, persistently advancing into the global high-end ultrasound field and accelerating its entry into core benchmark hospitals worldwide. Meanwhile, the ultrasound product line will focus on advantageous specialties such as obstetrics and gynecology and surgery, empowering diagnostic quality control and standardization with AI technology. Leveraging continuous iterations of high-end new products, the market position of the full product series will be further consolidated, and the ultrasound business is expected to maintain steady growth.
The endoscopy business, as a core growth engine, continued to maintain a high growth rate in the first quarter, further solidifying its leading position as a domestic endoscopy enterprise. In 2026, the company will take the launch of the new 4K iEndo smart endoscopy platform HD-650 as a key lever to promote the large-scale application of smart endoscopy solutions in tertiary hospitals and expand into departments such as respiratory and urology. Additionally, in March of this year, the newly certified U7 series modular ultrasound host further enhanced the company’s endoscopy product matrix, forming efficient synergies with high-end full-body ultrasound hosts and ultrasound endoscopy products. This creates distinctive integrated solutions such as “multi-scope combination,” continuously widening competitive barriers and driving the endoscopy business to maintain high growth.
Minimally invasive surgery, as a strategic new growth pole, has propelled the company’s rigid endoscope market share to fifth place domestically. Products such as the “Lingzhu Series” and “Jingwei Series,” which cover diverse clinical needs, saw significant volume growth in the first quarter and are accelerating toward large-scale installation. In 2026, the company will focus on promoting the “Zhihui Operating Room” and multi-scope combination solutions, deeply cultivating core departments such as hepatobiliary and gastroenterology. Leveraging its comprehensive technical advantages in soft and rigid endoscopy and ultrasound R&D, it aims to create a differentiated ecosystem, likely leading to continued rapid revenue growth in this business.
The cardiovascular intervention business continued its outstanding performance from 2025, with both implantation volume and revenue maintaining high growth in the first quarter. In 2026, the company’s new V-reader® V20 cart-based system has undergone a comprehensive upgrade, optimizing clinical operation experience and overall costs. Based on accumulated clinical reputation and admission foundations, the certainty of high growth for this business throughout the year has been further strengthened.
Notably, SonoScape Medical’s “Device + AI” integrated innovation layout has received national-level recognition once again. In January of this year, two cutting-edge projects led by the company—the “Coronary Intravascular Ultrasound Vulnerable Plaque Intelligent Assisted Identification System” and the “Multimodal Fusion Colorectal Adenoma Intelligent Assisted Diagnosis System”—were successfully selected for the national 2025 Artificial Intelligence Medical Device Innovation Task “Open Competition” shortlist, further highlighting the company’s leading strength in the integration and innovation of medical devices and AI.
As 2026 marks a critical year for the implementation and harvest of SonoScape Medical’s multi-product line strategy, the stable performance in the first quarter has laid a solid foundation for the full-year strategic rollout. Looking ahead, the company will continue to consolidate the high-end advantages of its ultrasound business, expand the leading share of its endoscopy business, accelerate the volume growth of its minimally invasive surgery and cardiovascular intervention businesses, seize opportunities from industry policy implementation and globalization, and empower long-term growth through the integration and innovation of “Device + AI” technology, striving to become a globally leading medical device enterprise.